

DEPARTMENT OF HEALTH AND HUMAN SERVICES

FEB 20 1991

Our Reference Nos.: 90-0066 and 90-0067.

N. Kirby Alton, Ph.D.
Amgen, Inc.
Amgen Center
Thousand Oaks, CA 91320-1789

Dear Dr. Alton:

Enclosed is a product license which authorizes Amgen, Inc., U.S. License No. 1080, to manufacture and ship for sale, barter, or exchange in interstate and foreign commerce, Filgrastim.

Filgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.

Your establishment license application is also amended to include the manufacture of Filgrastim with the stipulation that filling and finishing of final product will only be performed at the Rochester, MI location of Parke-Davis under a contractual arrangement. All Filgrastim manufacturing operations performed at Parke-Davis shall be under your direct supervision and control as specified in your establishment license application. The Thousand Oaks facility is not approved to fill or finish final product at this time.

You are requested to submit samples of each future lot of the product together with protocols showing results of all applicable tests. No lots of product shall be shipped for distribution until notification of release is received from the Director, Center for Biologics Evaluation and Research.

The dating period for this product shall be 24 months from the date of manufacture when stored at 2-8°C. The date of manufacture shall be defined as the date of the final sterile filtration of the bulk solution into final containers. Results of ongoing stability studies should be submitted at regular intervals as specified in your letter of January 4, 1991. The first three production lots should be entered into your ongoing stability program.

Any changes in the manufacturing, testing, packaging, or labeling of the product or in the manufacturing facilities will require the submission of an amendment to either your product or establishment license application for our review and written approval prior to implementation.

Page 2- Dr. Alton

We acknowledge receipt of your written commitments of January 8, 1991 to acquire additional data so that process specifications can be set for the percentage of the reduced form of Filgrastim.

You are requested to submit adverse experience reports in accordance with the requirements for postmarketing reporting of adverse drug experiences (21 CFR 314.80) until such time that specific reporting requirements for biological products become effective. All experience reports should be prominently labeled as "BIOLOGICAL PRODUCT" and be submitted to the attention of Biostatistics and Epidemiology, HFB-250, Office of Biological Product Review, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892.

Please submit three copies of final printed labeling at the time of use and include part II of the label transmittal form with completed implementation information.

In addition, advertising and promotional labeling should be submitted for review and approval prior to the initial publication of any advertisement and prior to the initial dissemination of any promotional labeling. All promotional claims must be consistent with and not contrary to approved labeling. No comparative promotional claim or claim of superiority over other similar products should be made unless data to support such claims are submitted to and approved by the Center for Biologics Evaluation and Research.

Please acknowledge receipt of the enclosed license to the Acting Director, Division of Product Certification, HFB-240, Center for Biologics Evaluation and Research.

Sincerely yours,

Gerald V. Quinnan, Jr., M.D.
Acting Director
Center for Biologics
Evaluation and Research